ReviewOncology reviews2026

Uncertain magnitude of benefit of early second-generation androgen receptor antagonist treatment in advanced prostate cancer.

Emma K van de Weerdt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.